Stifel reviews a broad rebound across biotech and pharma, noting that investor optimism and strategic deal-making have returned. The update explores how innovation, capital markets, and policy shifts are influencing sector direction, with attention on scientific progress and the reemergence of growth themes.
Date published: October 6, 2025